Guerrino Meneguzzi

Guerrino Meneguzzi

Auto-generated profile, based on publicly available information

Guerrino Meneguzzi

INSERM

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1994 in Matrix Biology
Verified
Journal Article
Closed access
RBR E Burgeson
R E Burgeson
MCM Chiquet
M Chiquet
RDR Deutzmann
R Deutzmann
PEP Ekblom
P Ekblom
JEJ Engel
J Engel
JSJ Sanes
J Sanes

1 August 2011 in Cancer Cell
Verified
Journal Article
Closed access
VSVictoria Sanz-Moreno
Victoria Sanz-Moreno
CGCedric Gaggioli
Cedric Gaggioli
MYMaggie Yeo
Maggie Yeo
JAJean Albrengues
Jean Albrengues
FWFredrik Wallberg
Fredrik Wallberg
CMChris J. Marshall
Chris J. Marshall

15 December 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
JAJean Albrengues
Jean Albrengues
TBThomas Bertero
Thomas Bertero
EGEloise Grasset
Eloise Grasset
SBStephanie Bonan
Stephanie Bonan
MMMajdi Maiel
Majdi Maiel
CGCedric Gaggioli
Cedric Gaggioli
Carcinoma-associated fibroblasts (CAF) mediate the onset of a proinvasive tumour microenvironment. The proinflammatory cytokine LIF reprograms fibroblasts into a proinvasive phenotype, which promotes extracellular matrix remodelling and collective invasion of cancer cells. Here we unveil that exposure to LIF initiates an epigenetic switch leading to the constitutive activation of JAK1/STAT3 signalling, which results in sustained proinvasive activity of CAF. Mechanistically, p300-histone acetyltransferase acetylates STAT3, which, in turn, upregulates and activates the DNMT3b DNA methyltransferase. DNMT3b methylates CpG sites of the SHP-1 phosphatase promoter, which abrogates SHP-1 expression, and results in constitutive phosphorylation of JAK1. Sustained JAK1/STAT3 signalling is maintained by DNA methyltransferase DNMT1. Consistently, in human lung and head and neck carcinomas, STAT3 acetylation and phosphorylation are inversely correlated with SHP-1 expression. Combined inhibition of DNMT activities and JAK signalling, in vitro and in vivo, results in long-term reversion of CAF-associated proinvasive activity and restoration of the wild-type fibroblast phenotype.

1 June 1995 in Nature Genetics
Verified
Journal Article
Closed access
FRFr
Fr
IAINSERM Aberdam
INSERM Aberdam
DD
D
[E[Eacute]
[Eacute]
RVRique Vidal
Rique Vidal
ACAngela M. Christiano
Angela M. Christiano

15 December 2003 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
SSSaeed Shafti-Keramat
Saeed Shafti-Keramat
AHAlessandra Handisurya
Alessandra Handisurya
EKErnst Kriehuber
Ernst Kriehuber
GMGuerrino Meneguzzi
Guerrino Meneguzzi
KSKatharina Slupetzky
Katharina Slupetzky
RKReinhard Kirnbauer
Reinhard Kirnbauer
Papillomaviruses replicate in stratified epithelia of skin and mucosa. Infection with certain human papillomavirus (HPV) types is the main cause of anogenital neoplasia, in particular cervical cancer. Early events of papillomavirus infectivity are poorly understood. While heparan sulfate proteoglycans (HSPGs) mediate initial binding to the cell surface, the class of proteins carrying heparan sulfates has not been defined. Here we examined two processes of papillomavirus infection, attachment of virus-like particles (VLP) to cells and infection with authentic HPV type 11 (HPV11) virions. Of the HSPGs, syndecan-1 is the major epithelial form and is strongly upregulated in wound edge keratinocytes. We employed K562 cells, which lack HSPGs except minor amounts of endogenous betaglycan, and stable clones that express cDNAs of syndecan-1, syndecan-4, or glypican-1. Binding of VLP correlated with levels of heparan sulfate on the cell surface. Parental K562 bound HPV16 VLP weakly, whereas all three K562 transfectants demonstrated enhanced binding, with the highest binding capacity observed for syndecan-1-transfected cells, which also expressed the most HSPG. For HPV11 infectivity assays, a high virion inoculum was required to infect K562 cells, whereas ectopic expression of syndecan-1 increased permissiveness eightfold and expression of syndecan-4 or glypican-1 fourfold. Infection of keratinocytes was eliminated by treatment with heparitinase, but not phospholipase C, further implicating the syndecan family of integral membrane proteins as receptor proteins. Human keratinocytes with a homozygous deletion of α6 integrin are permissive for HPV11 infection. These results indicate that several HSPGs can serve as HPV receptors and support a putative role for syndecan-1, rather than α6 integrin, as a primary receptor protein in natural HPV infection of keratinocytes.

1 June 2014 in Cell Reports
Verified
Journal Article
Open access
JAJean Albrengues
Jean Albrengues
IBIsabelle Bourget
Isabelle Bourget
CPCatherine Pons
Catherine Pons
VBVincent Butet
Vincent Butet
Paul HofmanPaul Hofman
Paul Hofman
CGCedric Gaggioli
Cedric Gaggioli
Signaling crosstalk between tumor cells and fibroblasts confers proinvasive properties to the tumor microenvironment. Here, we identify leukemia inhibitory factor (LIF) as a tumor promoter that mediates proinvasive activation of stromal fibroblasts independent of alpha-smooth muscle actin (α-SMA) expression. We demonstrate that a pulse of transforming growth factor β (TGF-β) establishes stable proinvasive fibroblast activation by inducing LIF production in both fibroblasts and tumor cells. In fibroblasts, LIF mediates TGF-β-dependent actomyosin contractility and extracellular matrix remodeling, which results in collective carcinoma cell invasion in vitro and in vivo. Accordingly, carcinomas from multiple origins and melanomas display strong LIF upregulation, which correlates with dense collagen fiber organization, cancer cell collective invasion, and poor clinical outcome. Blockade of JAK activity by Ruxolitinib (JAK inhibitor) counteracts fibroblast-dependent carcinoma cell invasion in vitro and in vivo. These findings establish LIF as a proinvasive fibroblast producer independent of α-SMA and may open novel therapeutic perspectives for patients with aggressive primary tumors.